Page 5 - T Cell News Today

Researchers developed the Splicing Neo Antigen Finder (SNAF) workflow, integrating deep learning to identify shared immunogenic neoantigens in cancers, offering new targets for cancer immunotherapy, particularly in melanoma and ovarian cancer.

Programmed cell death 1 (PD-1) is an important target for immune checkpoint inhibitor therapies that block its signaling and boost T-cell activity. PD-1 inhibitors have been approved for treating various types of cancer.

Study investigates the impact of helminth infection on COVID-19 mRNA vaccine efficacy, revealing that while antibody responses remain largely unaffected, T-cell responses are significantly impaired, particularly against Omicron variants.

First order for IV-Cell placed by Major Japanese Laboratory...

Beckman Coulter Life Sciences anti-TRBC2 conjugated antibody for flow cytometry and identification of T-cell neoplasms

Checking for and categorizing a suspected allergy allow physicians to draw up a management plan.

Study reveals robust memory T-cell responses to SARS-CoV-2 in healthcare workers over 1.5 years post-Omicron, suggesting durable immunity against highly mutated variants.

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, continues to lead the way with first-to-market concepts to help laboratories achieve goals faster and with greater accuracy.

The current achievements in the development of a pan-coronavirus vaccine.

Lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, is a cost effective second line treatment for relapsed and refractory (hard to treat) diffuse large B-cell lymphoma (r/r DLBCL), according to a study published today in Blood Advances.